Deakin University joins the Nicolas Baudin Internships in France Initiative

Christophe Penot, Ambassador of France to Australia, was welcomed on 20 November at Deakin University (Melbourne)  for a meeting devoted to the development of the university’s relations with France.

Picture by Simon Fox, Deakin University

The meeting highlighted some of the collaborations established between Deakin and France, which will be able to benefit from this program. In particular, research work brought up regarding the prevention and treatment of cancer, carried out in collaboration with the CNRS in the framework of the associated international CANECEV laboratory which was set up during the visit of the President of the Republic to Australia in May 2018.

Read more @ the Embassy of France in Canberra website.

World “One Health” Day 2018 @ Geelong Centre for Emerging Infectious Diseases

Join us on Nov 15 for GCEID’s World” One Health” Day. Hear @Deakin University researchers Dr Beata Ujvari talk about transmissible cancer in wildlife and Dr Daniel Dlugolenski talk about bird flu.

This event will showcase how researchers in Geelong are undertaking collaborative research to protect people, animals and the environment from infectious diseases.

This is an open house event, please feel free to drop in at any point throughout the day (this is a free event).

When: Thursday 15 November 2018 between 10am and 3pm.

Where: St Mary’s Building, 190 Myers Street, Geelong, 3220.

For more details and registration please visit GCEID’s website.

Social environment mediates cancer progression in Drosophila

Authors: Erika H. Dawson, Tiphaine P. M. Bailly, Julie Dos Santos, Céline Moreno, Maëlle Devilliers, Brigitte Maroni, Cédric Sueur, Andreu Casali, Beata Ujvari, Frederic Thomas, Jacques Montagne & Frederic Mery

SourceNature Communicationsvolume 9, Article number: 3574 (Published: 03 September 2018)

Brief summary of the paper: The influence of oncogenic phenomena on the ecology and evolution of animal species is becoming an important research topic.

Similar to host–pathogen interactions, cancer negatively affects host fitness, which should lead to the selection of host control mechanisms, including behavioral traits that best minimize the proliferation of malignant cells. Social behavior is suggested to influence tumor progression. While the ecological benefits of sociality in gregarious species are widely acknowledged, only limited data are available on the role of the social environment on cancer progression.

Here, we exposed adult Drosophila, with colorectal-like tumors, to different social environments. We show how subtle variations in social structure have dramatic effects on the progression of tumor growth.

Finally, we reveal that flies can discriminate between individuals at different stages of tumor development and selectively choose their social environment accordingly. Our study demonstrates the reciprocal links between cancer and social interactions and how sociality may impact health and fitness in animals and its potential implications for disease ecology.

Can species be genetically doomed? Watch Jay’s video assignment for honours 2018 @ Deakin University

We are happy to share Jay Fitzpatrick‘s video assignment for honours 2018 @ Deakin University, exploring a scientific paper that discovered that thylacines were genetically doomed before human settlement in Australia.

Jay Fitzpatrick  – Honours student, co-supervised with Dr Rodrigo Hamede from University of Tasmania.
Topic of research –  “the role of the innate immune system in DFTD progression and epidemiology“.

French president signs off on new cancer research collaboration with Deakin

Deakin University will collaborate with a group of French research institutions and the University of Tasmania on a new international cancer research laboratory, after a special agreement signed by French President Emmanuel Macron and Australian Prime Minister Malcolm Turnbull (May 2nd, 2018).

The collaboration will include formation of a Laboratoire International Associé – a ‘laboratory without walls’ – and will be part of a world-leading program established by France’s National Research Institute, the Centre National de la Recherche Scientifique (CNRS).

The laboratory project was spearheaded by Dr Beata Ujvari (leader of  the Wild Genes Group), a Senior Lecturer in Bioinformatics and Genomics at Deakin’s Centre for Integrative Ecology within the School of Life and Environmental Sciences, and CNRS Research Director Frederic Thomas, both of whom will be Scientific Coordinators of the LIA.

According to Dr Ujvari the laboratory would reshape the conceptual landscape of cancer biology, evolutionary ecology and biology, breaking new ground in its transdisciplinary approach.

More details available @ Deakin Media Releases.

4th International Biannual Evolution & Cancer Conference(Resistance, resilience and robustness: can we target cancer’s evolutionary and ecological nature?)

Authors: Benjamin Roche, Beata Ujvari & Frédéric Thomas

SourceEvolutionary Applications (21 February 2018)

Brief summary of the paper: Many biological systems are resilient to shock and have the ability to return to a previous state following a disturbance. In the case of cancer, this resilience may jeopardize our understanding of tumerous cell proliferation and presents many clinical problems, including therapeutic resistance.

Indeed, during progression and treatment, cancer has the capacity to exhibit resistance, resilience, and robustness, making its dynamics very challenging to forecast. Furthermore, organisms have evolved defenses that increase the robustness to mutations and other perturbations that can increase cancer susceptibility.

Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer

Authors: Kriti Ray, Beata Ujvari, Venkata Ramana & John Donald

Source: Cytokine & Growth Factor Reviews (Available online 7 April 2018)

Brief summary of the paper: Epidermal growth factor receptor (EGFR) is a known target in cancer therapy and targeting the receptor has proven to be extremely successful in treating cancers that are dependent on EGFR signaling.

To that effect, targeted therapies to EGFR such as Cetuximab, Panitumumab-monoclonal antibodies and Gefitinib, Erlotinib-tyrosine kinase inhibitors have had success in therapeutic scenarios. However, the development of resistance to these drugs makes it necessary to combine anti- EGFR therapies with other inhibitors, so that resistance can be overcome by the targeting of alternate signaling pathways.

On the other hand, components of the inflammatory pathway, within and around a tumor, provide a conducive environment for tumor growth by supplying numerous cytokines and chemokines that foster carcinogenesis. Interleukin 6 (IL-6) is one such cytokine that is found to be associated with inflammation-driven cancers and which also plays a crucial role in acquired resistance to anti-EGFR drugs. The EGFR and IL-6 signaling pathways crosstalk in multiple ways, through various mediators and downstream signaling pathways driving resistance and hence co-targeting them has potential for future cancer treatments.

Here we provide an overview on the crosstalk between the EGFR and IL-6 pathways, and discuss how co-targeting these two pathways could be a promising combination therapy of the future.